CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
The first use of Philips' breakthrough CavaClear solution to help patients with embedded IVC filters, including an athlete suffering from a 16-year old penetrating filter
Researchers have developed a plasma-based disinfectant generated with the help of cold atmospheric pressure plasma (CAP) which could act as a green decontaminant for Covid-19
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
An estimated 21 million American women experience BV
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Subscribe To Our Newsletter & Stay Updated
